Poly Medicure, a prominent Indian medical consumables manufacturer, has made a significant Cardiology Catheters Acquisition, agreeing to acquire Netherlands-based PendraCare Group companies. This strategic move includes PendraCare Holdings and Wellinq Medical from Wellinq Holdings B.V. The deal, valued at ₹188.5 crore for an initial 90 percent equity stake, aims to significantly expand Poly Medicure’s cardiology segment and European market presence. Consequently, this acquisition highlights the growing global ambitions of Indian medical device companies. [2, 4, 6, 8, 9]
Driving Growth in Cardiology Catheters Acquisition and Market Access
The agreement outlines an upfront purchase of 90 percent equity for ₹188.5 crore. The remaining 10 percent equity stake will be acquired in 2030, with additional consideration based on PendraCare’s actual EBITDA for calendar year 2029. Notably, the existing management, including CEO Sander Hartman, will continue to lead the business. Mr. Hartman will also retain 10 percent non-voting shares in the Group, ensuring continuity and leveraging existing expertise. This structure facilitates a smooth transition and operational stability. [2, 6, 8, 9]
PendraCare, an ISO certified developer of cardiology catheter solutions, operates across 35 international markets. Therefore, this acquisition provides Poly Medicure with immediate access to a robust local manufacturing and distribution network. Furthermore, PendraCare’s products are registered with key regulatory bodies such as FDA, MDD, and ANVISA, ensuring broad market acceptance and compliance. This regulatory alignment is crucial for expanding market penetration effectively. [4, 6, 8]
Strategic Synergies from the Cardiology Catheters Acquisition
In 2024, PendraCare reported a revenue of €9.9 million (approximately Rs 102 crore) with a profit-before-tax of €81 thousand (around Rs 83 lakh). The Indian device maker anticipates generating an additional €3-4 million in annual synergy (incremental revenue) over the next 3-4 years. According to Himanshu Baid, MD, Poly Medicure, “This move brings us a valuable, ‘made-in-Europe’ cardiology consumables business with FDA and CE-marked products and we believe we will deliver significant synergies for the combined business.” [2, 4, 8, 9]
Indeed, this marks Poly Medicure’s second acquisition in the European market, which accounts for one-third of its total sales. The company previously acquired Italy-based oncology device maker Plan1 Health S.R.L. This pattern demonstrates Poly Medicure’s commitment to strengthening its presence and product portfolio in the European medical market. Ultimately, such strategic expansions position the company for sustained international growth and innovation. [2, 8, 9]
Frequently Asked Questions
Q1: What is the primary purpose of Poly Medicure’s acquisition of PendraCare?
Poly Medicure’s primary purpose is to strengthen its cardiology consumables business, gain access to European manufacturing and distribution networks, and leverage PendraCare’s FDA and CE-marked cardiology catheter products for international market expansion. [2, 4, 6]
Q2: What are the expected financial benefits of this acquisition for Poly Medicure?
Poly Medicure expects to generate an additional €3-4 million in annual synergy (incremental revenue) over the next 3-4 years from the PendraCare acquisition, building on PendraCare’s 2024 revenue of €9.9 million. [2, 4, 9]
Q3: How does this acquisition fit into Poly Medicure’s broader strategy?
This acquisition aligns with Poly Medicure’s strategy of expanding its presence in the European medical market, which accounts for one-third of its total sales. It is the company’s second European buyout, following the acquisition of Plan1 Health S.R.L., an oncology device maker. [2, 8]
References
- Poly Medicure pumps Cardio plans with ₹190 Cr PendraCare buyout – ETHealthworld
- Poly Medicure to buy Dutch cardiology devices maker PendraCare – VCCircle
- Poly Medicure announces acquisition of PendraCare Group for Rs 188.5 Cr
- Poly Medicure to acquire Netherlands-based PendraCare for ₹188.5 crore | Industry News
- Poly Medicure to buy 90% stake in Pendracare Group for ₹188.5 crore | Markets News
- Poly Medicure Acquires PendraCare Group Stake – Rediff Money
Disclaimer: This article was automatically generated from publicly available sources and is provided for informational and educational purposes only. OC Academy does not exercise editorial control or claim authorship over this content. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider and refer to current local and national clinical guidelines.